Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. by Bassand, J-P et al.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CLINICAL RESEARCH
Atrial fibrillation
Two-year outcomes of patients with newly
diagnosed atrial fibrillation: results from
GARFIELD-AF
Jean-Pierre Bassand1,2*, Gabriele Accetta2, Alan John Camm3, Frank Cools4,
David A. Fitzmaurice5, Keith A.A. Fox6, Samuel Z. Goldhaber7, Shinya Goto8,
Sylvia Haas9, Werner Hacke10, Gloria Kayani2, Lorenzo G. Mantovani11,
Frank Misselwitz12, Hugo ten Cate13, Alexander G.G. Turpie14, and
Freek W.A. Verheugt15,16, and Ajay K. Kakkar2,17, for the GARFIELD-AF Investigators†
1University of Besanc¸on, Besanc¸on, France; 2Thrombosis Research Institute, Emmanuel Kaye Building, Manresa Road, London SW3 6LR, UK; 3St George’s University of London,
London, UK; 4AZ Klina, Brasschaat, Belgium; 5University of Birmingham, Edgbaston, Birmingham, UK; 6University of Edinburgh, Edinburgh, UK; 7Brigham and Women’s Hospital and
Harvard Medical School, Boston, MA, USA; 8Tokai University, Kanagawa, Japan; 9Formerly Technical University of Munich, Munich, Germany; 10University of Heidelberg, Heidelberg,
Germany; 11University of Milano-Bicocca, Milan, Italy; 12Bayer HealthCare Pharmaceuticals, Berlin, Germany; 13Cardiovascular Research Institute Maastricht, Maastricht, The
Netherlands; 14McMaster University, Hamilton, Canada; 15University Hospital, Nijmegen; 16Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands; and 17University College
London, London, UK
Received 27 October 2015; revised 30 March 2016; accepted 29 April 2016
Aims The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is
poorly defined, especially beyond the first year.
Methods
and results
GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of
17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles
for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4)
years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anti-
coagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic ther-
apy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence
interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all
three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sud-
den/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of
death and strokes for ,10%. Anticoagulant treatment was associated with a 35% lower risk of death.
Conclusion The most frequent of the three major outcome measures was death, whose most common causes are not known to be
significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of
NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting
modifiable, cause-specific risk factors for death.
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Introduction
Atrial fibrillation (AF), the most frequent of all cardiac arrhythmias,
is associated with an increased risk of stroke, systemic embolism
(SE), and heart failure. Patients with AF have a two-fold increased
risk of death compared with those without AF.1– 3 Anticoagulation
reduces the risk of stroke/SE and of death at the cost of an increased
risk of bleeding. Anticoagulation with vitamin K antagonists (VKAs)
or with the newer non-vitamin K antagonist oral anticoagulants
(NOACs) is recommended for patients with AF and at least one
additional risk factor for stroke, whereas antiplatelet (AP) therapy,
either as monotherapy or with concomitant anticoagulation, is indi-
cated in a specific subset of patients.3,4 Currently, there are very lim-
ited data on the extended time course of events after diagnosis of
non-valvular atrial fibrillation (NVAF) in large multinational
populations.
The Global Anticoagulant Registry in the FIELD–Atrial Fibrilla-
tion (GARFIELD-AF) is an ongoing, observational, worldwide study
of adults with newly diagnosed NVAF, which is governed by the
highest academic and ethical standards in the generation, dissemin-
ation, and communication of its research findings.5 The registry
plans to prospectively recruit 52 000 patients (representing all
ethnicities and care settings) in five consecutive cohorts from ran-
domly selected centres in 35 countries.
Here, we report 2-year event rates for all-cause mortality, stroke/
SE, and major bleeding for the first two cohorts (in 17 162 patients)
and the factors that have contributed to these events, namely base-
line characteristics and treatment.
Methods
Study design and participants
Men and women aged ≥18 years with NVAF diagnosed according to
standard local procedures within the previous 6 weeks, and with at least
one additional risk factor for stroke as judged by the investigator, are eli-
gible for inclusion. Risk factors are not prespecified in the protocol nor
are they limited to the components of existing risk stratification
schemes. The study excludes patients with a transient reversible cause
of NVAF and those for whom follow-up is not envisaged or possible.5
Consecutive patients are enrolled prospectively into five sequential
cohorts, with the aim of recruiting up to 52 000 patients. Investigator
sites have been selected randomly and represent the different care set-
tings in each participating country (office-based practice; hospital de-
partments—neurology, cardiology, geriatrics, internal medicine, and
emergency; anticoagulation clinics; and general or family practice).5,6
Ethics statement
Independent ethics committee and hospital-based institutional review
board approvals were obtained. The registry is being conducted in accord-
ance with the principles of the Declaration of Helsinki, local regulatory re-
quirements, and the International Conference on Harmonisation—Good
Pharmacoepidemiological and Clinical Practice guidelines. Written
informed consent is obtained from all study participants. Confidentiality
and anonymity of all patients recruited into this registry are maintained.
Procedures and outcome measures
Baseline data collected at inclusion included patient characteristics,
medical history, care setting, type of AF, date and method of diagnosis,
symptoms, and anticoagulant (AC) treatment (VKAs, factor Xa inhibi-
tors [FXas], and direct thrombin inhibitors [DTIs], as well as AP treat-
ment). Ethnicity was classified by the investigator in agreement with the
patient.5
Data on all components of the CHA2DS2-VASc and HAS-BLED risk
stratification schemes were collected to assess the risks of stroke and
bleeding retrospectively. Vascular disease was defined as peripheral ar-
tery disease and/or coronary artery disease (CAD) with a history of
acute coronary syndromes (ACS). Hypertension was defined as a docu-
mented history of hypertension or blood pressure .140/90 mmHg at
rest.
Collection of follow-up data occurred at 4-month intervals up to 24
months. Outcome measures included clinical events, therapy persist-
ence, and healthcare utilization.5,6 The incidences of stroke/SE, pulmon-
ary embolism, ACS, hospitalization, death (cardiovascular and
non-cardiovascular), heart failure (occurrence or worsening), and
bleeding (severity and location) were recorded. Submitted data were
examined for completeness and accuracy by the coordinating centre
(Thrombosis Research Institute [TRI], London, UK), and data queries
were sent to study sites.
Data collection/quality control/auditing
GARFIELD-AF data are captured using an electronic case report form
(eCRF) designed by Dendrite Clinical Systems Ltd (Henley-on-Thames,
UK). Oversight of operations and data management are managed by the
sponsor and coordinating centre (TRI), with support from Quintiles
(Durham, NC, USA), The University of Birmingham Department of Pri-
mary Care Clinical Sciences (Birmingham, UK), Thrombosis Research
Group—Brigham and Women’s Hospital (Boston, MA, USA), and AIX-
IAL (Paris, France). The GARFIELD-AF protocol requires that 20% of all
eCRFs are monitored against source documentation, that there is an
electronic audit trail for all data modifications, and that critical variables
are subjected to additional audit.5 Data for the analysis in this report
were extracted from the study database on 3 August 2015.
Statistical analysis
Continuous variables are expressed as mean+ SD and categorical vari-
ables as frequency and percentage. Use of antithrombotic therapy at
baseline was analysed by CHA2DS2-VASc and ‘modified’ HAS-BLED
(excluding fluctuations in the international normalized ratio) scores, cal-
culated retrospectively from the data collected. Patients with missing va-
lues were not removed from the study.
Occurrence of major clinical outcomes is described using the number
of events, the proportion of patients with the event divided by the popu-
lation at risk at the beginning of the follow-up period, person-time event
rate (per 100 person-years), and 95% confidence interval (CI). We es-
timated person-year rates using a Poisson model, with the number of
events as the dependent variable and the log of time as an offset, i.e. a
covariate with a known coefficient of 1. Only the first occurrence of
each event was taken into account. The 4-monthly event rates were
compared with the overall rates using the ratio between the observed
and expected numbers of events (applying the overall rate to assess ex-
pected rates for that period). The Poisson trend statistic was used to as-
sess the trends over time. Hazard ratios (HRs) were estimated using a
proportional hazards Cox model after multiple imputation by the Mul-
tiple Imputation by Chained Equations (MICE) algorithm.7,8 We used
the MICE algorithm to fill in missing values, creating five complete data-
sets. Data analysis was performed at the TRI with SAS version 9.4 (SAS
Institute Inc., Cary, NC, USA) and Stata Statistical Software: Release 13
(StataCorp, College Station, TX, USA).
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Results
Study population
A total of 17 162 patients with NVAF were prospectively enrolled in
the first and second GARFIELD-AF cohorts between March 2010
and June 2013 and are included in this analysis. Patients in these co-
horts were recruited from 858 randomly selected study sites repre-
sentative of routine practice in each of 30 countries. Two-year
follow-up was achieved in 97% of patients.
At baseline, mean (SD) age was 69.8 (11.4) years, and 43.8% of
patients were female. The mean (SD) CHA2DS2-VASc and
HAS-BLED scores were 3.3 (1.6) and 1.5 (0.9), respectively. Other
baseline characteristics are shown in Table 1. At diagnosis of AF,
60.8% of patients were prescribed AC therapy (50.0% VKAs
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Table 1 Baseline characteristics of all patients
Variable Value %
Female, n/n (%) 7518/17 162 43.8
Age, mean (SD) (years) 69.8 (11.4) n/a
Age group, n/n (%)
,65 years 5094/17 162 29.7
65–69 years 2506/17 162 14.6
70–74 years 3027/17 162 17.6
≥75 years 6535/17 162 38.1
Race, n/n (%)
Caucasian 11 078/17 162 64.5
Hispanic/Latino 1260/17 162 7.3
Afro-Caribbean 26/17 162 0.2
Asian (not Chinese) 3004/17 162 17.5
Chinese 977/17 162 5.7
Mixed/other 286/17 162 1.7
Unwilling to declare/not recorded 531/17 162 3.1
Body mass index, mean (SD) (kg/m2) 27.8 (5.4) n/a
Pulse, mean (SD) (b.p.m.) 89.9 (26.7) n/a
Systolic blood pressure, mean (SD) (mmHg) 133.9 (19.9) n/a
Diastolic blood pressure, mean (SD) (mmHg) 80.0 (12.7) n/a
Left ventricular ejection fraction ,40%, n/n (%) 973/9744 10.0
Type of AF, n/n (%)
Permanent 2243/17 160 13.1
Persistent 2679/17 160 15.6
Paroxysmal 4332/17 160 25.2
New (newly diagnosed/new onset) 7906/17 160 46.1
Medical history, n/n (%)
Congestive heart failure 3532/17 160 20.6
Coronary artery disease 3416/17 160 19.9
Acute coronary syndromes 1614/17 157 9.4
Carotid occlusive disease 507/17 148 3.0
Pulmonary embolism or deep vein
thrombosis
478/17 150 2.8
Coronary artery bypass graft 503/16 654 3.0
Stroke/transient ischaemic attack 2186/17 160 12.7
Systemic embolism 109/17 150 0.6
History of bleeding 497/17 149 2.9
History of hypertension 13 396/17 160 78.1
Hypercholesterolaemia 6875/17 153 40.1
Diabetes 3750/17 160 21.9
Cirrhosis 94/17 148 0.5
Chronic kidney disease, n/n (%)
None or mild (Grades I and II) 15 399/17 159 89.7
Moderate to severe (Grades III to V) 1760/17 159 10.3
Dementia 264/17 153 1.5
Alcohol consumption, n/n (%)
Abstinent/light 12 980/14 727 88.1
Moderate 1369/14 727 9.3
Heavy 378/14 727 2.6
Current/previous smoker, n/n (%) 5475/15 621 35.0
Continued
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Table 1 Continued
Variable Value %
Antithrombotic treatment, n/n (%)
Vitamin K antagonists 6334/16 873 37.5
Vitamin K antagonists + antiplatelet 2103/16 873 12.5
Factor Xa inhibitors 637/16 873 3.8
Factor Xa inhibitors + antiplatelet 287/16 873 1.7
Direct thrombin inhibitors 685/16 873 4.1
Direct thrombin inhibitors + antiplatelet 210/16 873 1.2
Antiplatelet only 4627/16 873 27.4
None 1990/16 873 11.8
CHA2DS2-VASc score, mean (SD) 3.3 (1.6) n/a
CHA2DS2-VASc score categories, n/n (%)
0 381/16 699 2.3
1 1965/16 699 11.8
2 3220/16 699 19.3
3 3988/16 699 23.9
4 3681/16 699 22.0
5 2020/16 699 12.1
6–9 1444/16 699 8.6
HAS-BLED score, mean (SD) 1.5 (0.9) n/a
HAS-BLED score categories, n/n (%)
0 1463/10 863 13.5
1 4428/10 863 40.8
2 3542/10 863 32.6
3 1217/10 863 11.2
4 189/10 863 1.7
5 23/10 863 0.2
6–9 1/10 863 ,0.1
Care setting speciality at diagnosis, n/n (%)
Internal medicine 3378/17 160 19.7
Cardiology 10 614/17 160 61.9
Neurology 375/17 160 2.2
Geriatrics 78/17 160 0.5
Primary care/general practice 2715/17 160 15.8
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and 10.8% NOACs, with or without AP), 27.4% received AP
monotherapy, and 11.8% received no AC or AP therapy. The pro-
portion of patients receiving AC therapy (with or without AP) in-
creased with CHA2DS2-VASc score, being lowest for patients
with a score of 0 (41.6%) and highest for patients with a score
of 5 (67.5%; Cuzick test,9 P, 0.001; Figure 1A). The use of AC
(with or without AP) decreased with increasing HAS-BLED score,
from 76.5 to 49.8% for patients with scores of 0 and ≥4, respect-
ively (Cuzick test, P, 0.001; Figure 1B). Anticoagulant therapy
was not prescribed in 36.9% of patients with CHA2DS2-VASc
≥2. Patients not receiving AC therapy tended to be younger
(mean [SD] age 68.6 [12.3] vs. 70.6 [10.8] years; P , 0.001),
were more likely to have paroxysmal AF [29.6 vs. 22.3%;
P , 0.001], and had a lower mean (SD) CHA2DS2-VASc score
(3.0 [1.6] vs. 3.4 [1.6]; P , 0.001) but a higher mean (SD)
HAS-BLED score (1.7 [0.9] vs. 1.5 [1.0]; P, 0.001) than patients
receiving AC therapy.
Clinical outcomes
During the 2-year follow-up, the rates (95% CI) of all-cause mortal-
ity, stroke/SE, and major bleeding (first occurrences) were 3.83
(3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-
years, respectively (Table 2). The rates of all three major events
were significantly higher during the first 4 months of follow-up
(mortality +29%; stroke/SE +35%; major bleeding +56%) com-
pared with the overall event rates (Figure 2 and see Supplementary
material online, Table S1). Beyond the first 4 months, the rates of
events were lower and modestly declined over the course of
follow-up (x2 test for trend, P, 0.001 for mortality and stroke/
SE, P ¼ 0.001 for major bleeding). The early higher risk of death
was observed irrespective of AF pattern, but was higher with new
(newly diagnosed/new onset) AF than with other patterns of AF
(standardized mortality rate 1.41 [95% CI 1.19; 1.66] vs. 1.19
[1.00; 1.41], respectively). The same was also true for major bleed-
ing, with standardized incidence rates of 1.70 (95% CI 1.19; 2.44) vs.
1.43 (1.01; 2.03), respectively, for new AF compared with other AF
patterns. No difference in early excess of risk was observed for
stroke/SE.
The rate of death due to cardiovascular causes including fatal
bleeds was 1.55 (1.42; 1.70) per 100 person-years (Table 2). The
most frequent causes of cardiovascular death were congestive heart
failure (CHF), sudden or unwitnessed death, ACS, and ischaemic
stroke (Table 3). The rate of non-cardiovascular causes of death
was lower (1.37 [1.25; 1.51] per 100 person-years) and mainly
due to malignancy, respiratory failure, and infection/sepsis (Table 3).
The primary cause of death could not be identified in 280 of 1181
deaths. By multivariate analysis, the baseline variables significantly
associated with a higher risk of death were older age, diabetes mel-
litus, CHF, vascular disease, history of stroke/SE, history of bleeding,
chronic kidney disease (CKD), smoking, and non-paroxysmal forms
of AF. Anticoagulation was associated with a significantly lower risk
of death (Figure 3).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Event rates (per 100 person-years) for
selected clinical outcomes at 2 years of follow-upa
Rate (95% CI)
Death 3.83 (3.62; 4.05)
Cardiovascular death 1.55 (1.42; 1.70)
Non-cardiovascular death 1.37 (1.25; 1.51)
Undetermined cause 0.91 (0.81; 1.02)
Stroke/SE 1.25 (1.13; 1.38)
Major bleeding 0.70 (0.62; 0.81)
Acute coronary syndromes 0.63 (0.55; 0.73)
Congestive heart failureb 2.41 (2.24; 2.59)
CI, confidence interval; SE, systemic embolism.
aOnly the first occurrence of each event was taken into account.
bOccurrence of new CHF or worsening of pre-existing CHF.
Figure 1 Antithrombotic treatment at baseline stratified by
CHA2DS2-VASc score (A) and by HAS-BLED score (B).
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The rates of different types of stroke are detailed in Table 3, along
with the rates of bleeding events of different severity. Strokes were
predominantly ischaemic, and primary haemorrhagic strokes were
very uncommon. Sixty patients died from ischaemic stroke, 5 from
haemorrhagic stroke, and 89 patients who survived a stroke died
over the course of follow-up. The most frequent site for bleeding
events was the gastrointestinal tract (occurring in 1.47% of the total
population). Bleeds in a critical organ (intra-ocular/retinal, intra-spinal,
haemo-pericardium, haemothorax, retroperitoneal) and intracranial
bleeding (epidural/subdural haematomas) each occurred in 0.22%
of the population.
At 2-year follow-up, the rates of ACS and CHF were 0.63 (95% CI
0.55; 0.73) and 2.41 (2.24; 2.59) per 100 person-years, respectively
(Table 2).
The rates of death, stroke/SE, and major bleeding increased pro-
gressively with increasing grades of the CHA2DS2-VASc and
HAS-BLED scoring schemes (Cuzick test, P, 0.001; see Sup-
plementary material online, Figure S1) and correspondingly, the
HRs for death, stroke/SE, and major bleeding correlated with the
CHA2DS2-VASc and HAS-BLED scores (Figure 4).
Discussion
Analyses of event rates from the GARFIELD-AF registry have iden-
tified that death was the most frequent major adverse clinical event
over 2 years of follow-up in patients with NVAF. The rate of death
was three-fold higher than the rate of stroke/SE and more than
five-fold higher than the rate of major bleeding. The highest
frequency of events (for each major outcome measure) occurred
during the first 4 months of follow-up. The early risks of death
and major bleeding (but not stroke/SE) were higher with new
(newly diagnosed/new onset) NVAF than with the other patterns of
NVAF. These data suggest that incident NVAF may occur as a compli-
cation of a chronic or acute cardiovascular or non-cardiovascular
underlying disease that impairs early evolution.10–13 In addition, fluc-
tuations in AC control, which are commonly observed after the initi-
ation of VKA therapy, may explain, at least in part, the early excess of
Figure 2 Four-monthly rate ratios* for all-cause mortality (A),
stroke/systemic embolism (B), and major bleeding (C). *The ratio
between the observed number of events in the period and the ex-
pected number of events obtained by applying the overall rate to
the period. Only the first occurrence of each event was taken into
account.
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Table 3 Breakdown of primary outcomes by type of
event at 2-year follow-upa
Event N %
All-cause death 1181
Cardiovascular causes 478 40.5
Congestive heart failure 128 10.8
Sudden or unwitnessed death 89 7.5
Acute coronary syndromes 70 5.9
Ischaemic stroke 60 5.1
Otherb 131 11.1
Non-cardiovascular causes 423 35.8
Malignancy 121 10.3
Respiratory failure 95 8.0
Infection/sepsis 79 6.7
Otherc 128 10.8
Undetermined causes 280 23.7
Stroke (not including systemic embolism) 365
Primary ischaemic 260 71.2
Secondary haemorrhagic ischaemic 15 4.1
Primary intracerebral haemorrhage 37 10.1
Intracerebral 20 5.5
Intraventricular 5 1.4
Subarachnoid 3 0.8
Undeterminedd 9 2.5
Undeterminede 68 18.6
Bleeding events (not including minor bleeds) 504
Severity of bleed
Non-major, clinically relevant 288 57.1
Major 216 42.9
Fatalf 24 4.8
aOnly the first occurrence of each event was taken into account.
bIncludes deaths due to intracranial haemorrhage, atherosclerotic vascular disease,
dysrhythmia, pulmonary embolism, and haemorrhagic stroke.
cIncludes deaths due to accidents/trauma, renal disease, and liver disease.
dIncludes patients with unknown type of primary intracerebral haemorrhage and
patients with combinations of types of stroke.
eIncludes patients with unknown types of stroke and those with both primary
ischaemic and primary intracerebral haemorrhagic strokes.
fAll fatal bleeds are included in major bleeds and are also included in the mortality
analysis.
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events, as suboptimal VKA control was shown to result in higher rates
of stroke/SE, bleeding, and death.14 Furthermore, higher rates of is-
chaemic events have been observed at the initiation of warfarin in
VKA-naive patients, possibly linked to a transient hypercoagulable
state due to differential depletion of certain vitamin K-dependent clot-
ting factors.15 Marked hypercoagulability when NVAF first becomes
clinically apparent may also play a role. The decline in the rates of
events after 4 months (Figure 2 and see Supplementary material online,
Table S1) may be related to better AC control and/or to a change in
the risk profile of patients over time, and also to the fact that the sick-
est patients suffered their first event early on after diagnosis of NVAF.
A further important finding relates to the causes of death. As in
most12,16,17 but not all reports,18,19 cardiovascular and non-
cardiovascular deaths occurred at quite similar rates, but ischaemic
and haemorrhagic strokes were clearly not the main drivers of mor-
tality risk, since they accounted for fewer than 10% of all known
causes of death.19,20 Such a low rate of stroke-related death may
be because.60% of the population was anticoagulated. In contrast,
the most frequent causes of death, namely CHF, sudden or unwit-
nessed death, ACS, malignancy, respiratory failure, and infection/
sepsis, which accounted for 65% of all known causes of death (Ta-
ble 3), are not, or only modestly, affected by AC therapy. Neverthe-
less, AC therapy was associated with a 35% lower risk of death.
Evidently, AC therapy has a favourable impact on the risk of
stroke-related death, but part of the reduction in mortality risk is
most probably the consequence of prevention of thromboembol-
ism other than stroke/SE, associated with venous thromboembol-
ism in CHF and malignancy. In addition, occurrence and/or
complications of ACS can potentially be prevented by AC treat-
ment, as supported by trial data of anticoagulation after myocardial
infarction or ACS.21 Conversely, patients without AC treatment (al-
most 40% of the total population) had a worse outcome compared
with anticoagulated patients, despite the fact that they were younger
and had a lower risk of stroke.
Newly diagnosed NVAF, in this context, could represent a marker
of early death, as a consequence of worsening baseline disease, since
survival from several comorbidities, such as CHF, ACS, and respira-
tory failure, is affected by the occurrence of AF.22–26 Conversely, co-
morbidities/risk factors may affect the course of NVAF over time,
through gradual remodelling of heart chambers triggered by uncon-
trolled hypertension, progression of CAD, worsening of heart failure,
and also ageing that may precipitate the evolution of persistent or par-
oxysmal NVAF towards permanent NVAF.22,24,26 – 28 Concomitant
with these observations is the strikingly high rate of worsening of
heart failure (and to a lesser extent, the rate of new ACS) recorded
in these patients (Table 2). Both conditions are risk factors and causes
of death, but they are also precipitating factors for the occurrence and
progression of AF, and furthermore, they are worsened by the occur-
rence of AF.22–26,29
The CHA2DS2-VASc score was shown to be an equally good
predictor of the risks of all three outcome measures (Figure 4).
Most of the variables strongly associated with the risk of death,
namely older age, CHF, history of bleeding, CKD, diabetes melli-
tus, smoking, and pattern of AF, were also associated with the risk
of stroke/SE (data not shown). This seems to indicate that the
overall prognosis of NVAF in terms of death, stroke/SE and, to
some extent, bleeding is tightly linked to the same risk factors/
comorbidities.
Study limitations
Most study patients were Caucasians and, to a lesser extent, Asians.
Hispanic/Latino and Afro-Caribbean ethnicities were less repre-
sented in this analysis of the first two cohorts because recruitment
did not start at the same time in all countries involved in
GARFIELD-AF.
Study strengths
Several surveys, registries, and regional or national healthcare data-
bases have reported outcomes for patients with NVAF but most
studies had a limited duration of follow-up.30–37 Prior studies vary
in terms of inclusion criteria, duration of follow-up, and care set-
tings, and in the characterization of outcome events. In contrast,
the design of the GARFIELD-AF registry is unique; it has a global
reach and extended follow-up and incorporates patients with newly
diagnosed NVAF from all care settings, making it representative of
Figure 3 Adjusted hazard ratios for 2-year all-cause mortality
according to baseline characteristics and anticoagulant treatment.
Anticoagulant treatment includes both vitamin K antagonists and
non-vitamin K antagonist oral anticoagulants. Hazard ratios were
adjusted for all variables in the model. Reference groups, from
top: ,65 years, men, Caucasian/Hispanic/Latino, never smoker,
no history of disease (for diabetes, hypertension, stroke/TIA/sys-
temic embolism, history of bleeding, cardiovascular failure, vascu-
lar disease, and renal disease), no anticoagulant treatment, and
paroxysmal AF. TIA, transient ischaemic attack.
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real-life management of NVAF worldwide. In addition, GARFIELD-
AF audit and quality assurances exceed the standards of most
large-scale registries and even some randomized trials.5
Conclusions
Death was the most frequent adverse outcome in NVAF. The high-
est event rates for death, stroke/SE, and major bleeding occurred
during the first 4 months of follow-up, gradually diminishing over
time. Stroke-related mortality was not the most frequent cause of
death, suggesting that a more comprehensive approach to the man-
agement of patients with NVAF may be needed to improve out-
come. This could include interventions targeting other modifiable,
cause-specific risk factors for death (such as CHF, CAD, ACS,
diabetes, and hypertension) in addition to anticoagulation.20,23
CHA2DS2-VASc and HAS-BLED scores were both predictive of
all three major outcome measures, suggesting that a single inte-
grated risk score derived from a large cohort of patients like the
GARFIELD-AF registry, encompassing all three major outcome
measures, may have an added value compared with existing risk
scores.
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